MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejmech.2021.113823

Медицинская библиотека · European journal of medicinal chemistry · 2021

Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.

Padalino Gilda, El-Sakkary Nelly, Liu Lawrence J, Liu Chenxi, Harte Danielle S G, Barnes Rachel E, Sayers Edward, Forde-Thomas Josephine, Whiteland Helen, Bassetto Marcella, Ferla Salvatore, Johnson George, Jones Arwyn T, Caffrey Conor R, Chalmers Iain, Brancale Andrea, Hoffmann Karl F

СтатьяПеревод в очереди

Аннотация

Schistosomiasis is a neglected disease of poverty that is caused by infection with blood fluke species contained within the genus Schistosoma. For the last 40 years, control of schistosomiasis in endemic regions has predominantly been facilitated by administration of a single drug, praziquantel. Due to limitations in this mono-chemotherapeutic approach for sustaining schistosomiasis control into the future, alternative anti-schistosomal compounds are increasingly being sought by the drug discovery community. Herein, we describe a multi-pronged, integrated strategy that led to the identification and further exploration of the quinoxaline core as a promising anti-schistosomal scaffold. Firstly, phenotypic screening of commercially available small molecules resulted in the identification of a moderately active hit compound against Schistosoma mansoni (1, EC50 = 4.59 μM on schistosomula). Secondary exploration of the chemical space around compound 1 led to the identification of a quinoxaline-core containing, non-genotoxic lead (compound 22). Compound 22 demonstrated substantially improved activities on both intra-mammalian (EC50 = 0.44 μM, 0.20 μM and 84.7 nM, on schistosomula, juvenile and adult worms, respectively) and intra-molluscan (sporocyst) S. mansoni lifecycle stages. Further medicinal chemistry optimisation of compound 22, resulting in the generation of 20 additional analogues, improved our understanding of the structure-activity relationship and resulted in considerable improvements in both anti-schistosome potency and selectivity (e.g. compound 30; EC50 = 2.59 nM on adult worms; selectivity index compared to the HepG2 cell line = 348). Some derivatives of compound 22 (e.g. 31 and 33) also demonstrated significant activity against the two other medically important species, Schistosoma haematobium and Schistosoma japonicum. Further optimisation of this class of anti-schistosomal is ongoing and could lead to the development of an urgently needed alternative to praziquantel for assisting in schistosomiasis elimination strategies.

Для цитирования: Padalino Gilda, El-Sakkary Nelly, Liu Lawrence J, Liu Chenxi, Harte Danielle S G, Barnes Rachel E, Sayers Edward, Forde-Thomas Josephine, Whiteland Helen, Bassetto Marcella, Ferla Salvatore, Johnson George, Jones Arwyn T, Caffrey Conor R, Chalmers Iain, Brancale Andrea, Hoffmann Karl F. Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.. European journal of medicinal chemistry. 2021. DOI: 10.1016/j.ejmech.2021.113823.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.